PURPOSE: Aim of this analysis was to assess the current status of prostate cancer radiotherapy in Austria and compare these numbers to patients treated with surgery. MATERIAL AND METHODS: A questionnaire was sent to all 14 Austrian departments asking about numbers of prostate cancer patients treated and indication of treatment (primary, postoperative), as well as the treatment technique used (3D-CRT, IMRT, brachytherapy), treatment volumes (with/without pelvic irradiation), dose applied, and differences in treatment concepts. Data investigated were based on the year 2007. RESULTS: Of the 14 departments (65%), 9 departments decided to participate. A total of 1,191 prostate cancer patients were treated (847 primary, 344 postoperative). Primary patients were treated by external beam technique (91%) and permanent interstitial brachytherapy (9%). All postoperative patients were treated by 3D-CRT. Dose ranged from 70-78 Gy for primary patients and from 60-72 Gy for postoperative patients. A risk-adapted dose prescription was performed in 5 centers. Additional pelvic lymph node irradiation was based on signs of positive nodes in 4 departments and based on Roach formula/Partin table in 5 departments. CONCLUSION: About 25% of prostate cancer patients receive primary radiotherapy. This number reflects a high potential to conduct national studies. Treatment technique and dose applied was in all centers investigated in accordance with the German S3 guidelines.
PURPOSE: Aim of this analysis was to assess the current status of prostate cancer radiotherapy in Austria and compare these numbers to patients treated with surgery. MATERIAL AND METHODS: A questionnaire was sent to all 14 Austrian departments asking about numbers of prostate cancerpatients treated and indication of treatment (primary, postoperative), as well as the treatment technique used (3D-CRT, IMRT, brachytherapy), treatment volumes (with/without pelvic irradiation), dose applied, and differences in treatment concepts. Data investigated were based on the year 2007. RESULTS: Of the 14 departments (65%), 9 departments decided to participate. A total of 1,191 prostate cancerpatients were treated (847 primary, 344 postoperative). Primary patients were treated by external beam technique (91%) and permanent interstitial brachytherapy (9%). All postoperative patients were treated by 3D-CRT. Dose ranged from 70-78 Gy for primary patients and from 60-72 Gy for postoperative patients. A risk-adapted dose prescription was performed in 5 centers. Additional pelvic lymph node irradiation was based on signs of positive nodes in 4 departments and based on Roach formula/Partin table in 5 departments. CONCLUSION: About 25% of prostate cancerpatients receive primary radiotherapy. This number reflects a high potential to conduct national studies. Treatment technique and dose applied was in all centers investigated in accordance with the German S3 guidelines.
Authors: Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-31 Impact factor: 7.038
Authors: Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Gemma Gatta; Giulia Zigon; Antoine Buemi; Jan Willem Coebergh; Marc Colonna; Paolo Contiero; Louis Denis; Pascale Grosclaude; Ann Valèrie Guizard; Maria Jose Sanchez-Perez; Ivan Plesko; Martina Ondrusova; Jadwiga Rachtan; Riccardo Valdagni; Michael Velten; Marina Vercelli; Franco Berrino Journal: Acta Oncol Date: 2009 Impact factor: 4.089
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Gregor Goldner; Valentin Bombosch; Hans Geinitz; Gerd Becker; Stefan Wachter; Stefan Glocker; Frank Zimmermann; Natascha Wachter-Gerstner; Andrea Schrott; Michael Bamberg; Michael Molls; Horst Feldmann; Richard Pötter Journal: Strahlenther Onkol Date: 2009-02-25 Impact factor: 3.621
Authors: G Goldner; R Pötter; J J Battermann; M P Schmid; C Kirisits; S Sljivic; M van Vulpen Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: E Le Fur; J P Malhaire; D Baverez; F Delage; M A Perrouin-Verbe; F Schlurmann; S Guerif; G Fournier; O Pradier; A Valeri Journal: Strahlenther Onkol Date: 2012-11-11 Impact factor: 3.621
Authors: M Pinkawa; M D Piroth; R Holy; N Escobar-Corral; M Caffaro; V Djukic; J Klotz; M J Eble Journal: Strahlenther Onkol Date: 2012-08-31 Impact factor: 3.621
Authors: Cédric M Panje; Alan Dal Pra; Thomas Zilli; Daniel R Zwahlen; Alexandros Papachristofilou; Fernanda G Herrera; Oscar Matzinger; Ludwig Plasswilm; Paul Martin Putora Journal: Strahlenther Onkol Date: 2015-05-19 Impact factor: 3.621
Authors: Marco M E Vogel; Sabrina Dewes; Eva K Sage; Michal Devecka; Jürgen E Gschwend; Kilian Schiller; Stephanie E Combs Journal: Strahlenther Onkol Date: 2021-01-27 Impact factor: 3.621